Demographics and clinical characteristics of participants who completed the online survey
| Parameters | Quantitative phase II (n=1050) |
| Age, years, mean±sd | |
| At survey | 60.5±11.0 |
| At diagnosis | 53.6±11.3 |
| Time since diagnosis, years, mean±sd | 7.2±7.0 |
| Age groups % | |
| 40–59 years | 45 |
| 60–79 years | 50 |
| >80 years | 5 |
| Sex, male % | 51 |
| Country n (%) | |
| USA | 400 (38.1) |
| UK | 200 (19.0) |
| France | 150 (14.3) |
| Australia | 150 (14.3) |
| Japan | 150 (14.3) |
| Body mass index % (n=954) | |
| Underweight (<18.5 kg·m−2) | 4 |
| Healthy (18.5–24.9 kg·m−2) | 44 |
| Overweight (25.0–29.9 kg·m−2) | 28 |
| Obese (>30 kg·m−2) | 24 |
| Smoking status % | |
| Current smokers | 29 |
| Ex-smokers | 57 |
| Never-smokers | 14 |
| Comorbidities % | |
| Asthma | 44 |
| Hypertension | 40 |
| Allergies | 34 |
| Depression/anxiety | 25 |
| Gastro-oesophageal reflux disorder | 22 |
| Sleep disturbance | 31 |
| Diabetes | 17 |
| Obesity | 16 |
| Osteoporosis | 16 |
| Urinary incontinence | 15 |
| Rheumatology disease | 15 |
| COPD severity (self-perceived) % | |
| Mild | 11 |
| Moderate | 54 |
| Severe/very severe | 35 |
| Severity derived from PRO instruments#, mean±sd | |
| CAT score | 25.0±6.67 |
| CASA-Q score | 50.3±20.9 |
| Exacerbations in the past 12 months¶% | |
| 0 | 29 |
| 1 | 24 |
| 2 | 22 |
| ≥3 | 25 |
| Amount of mucus when coughing in the past 7 days % | |
| A great/very great deal | 35 |
| Some/a little | 62 |
| None at all | 3 |
| Asthma/respiratory allergy % | |
| Since childhood | 23 |
| Since adulthood | 42 |
| No allergy | 35 |
| Educational qualification (higher college or university degrees) % | |
| USA | 68 |
| UK | 48 |
| France | 72 |
| Australia | 59 |
| Japan | 86 |
| Employment status % | |
| Retired | 42 |
| Currently full time | 34 |
| Other (working part time, home maker, on sick leave, student and unemployment) | 24 |
PRO: patient-reported outcome; CAT: COPD Assessment Test; CASA-Q: Cough and Sputum Assessment Questionnaire. #: CAT scores range from 0 to 40; higher scores denote a more severe impact of COPD on a patient's life; and CASA-Q domain scores range from 0 to 100, with higher scores associated with fewer symptoms/less impact due to cough or sputum. ¶: that required hospitalisation; higher scores denote a more severe impact of COPD on a patient's life.